S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:REUN

Reunion Neuroscience (REUN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.12
$1.12
50-Day Range
$1.11
$1.13
52-Week Range
$0.63
$5.07
Volume
N/A
Average Volume
210,209 shs
Market Capitalization
$13.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
REUN stock logo

About Reunion Neuroscience Stock (NASDAQ:REUN)

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

REUN Stock News Headlines

The Perks of Yearning
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Reunion Neuroscience (REUN) Earnings Dates & Reports
See More Headlines
Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:REUN
Employees
16
Year Founded
N/A

Profitability

Net Income
$-36,690,000.00
Pretax Margin
-2,583.10%

Debt

Sales & Book Value

Annual Sales
$3.88 million
Book Value
$1.37 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.13 million
Optionable
Not Optionable
Beta
2.29
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Hannan Fleiman (Age 42)
    Co-Founder & Non-Independent Director
    Comp: $214.69k
  • Dr. Nathan Bryson B.Sc. (Age 59)
    Ph.D., Chief Science Officer
    Comp: $312.47k
  • Mr. Gregory T. Mayes Esq. (Age 54)
    J.D., Pres, CEO & Director
  • Mr. Edward F. Smith CPA (Age 52)
    Chief Financial Officer
  • Mr. Curtis Weber
    Gen. Counsel
  • Mr. Stephan Cote
    Head of Quality
  • Dr. Robert Alexander M.D.
    Chief Medical Officer & Sr. Advisor

REUN Stock Analysis - Frequently Asked Questions

Should I buy or sell Reunion Neuroscience stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reunion Neuroscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REUN shares.
View REUN analyst ratings
or view top-rated stocks.

This page (NASDAQ:REUN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners